Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
Active Not Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS). COVID-19 sub-study: The purpose of... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +295 locations
Conditions: Relapsing Multiple Sclerosis
Register for Updates
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
NCT03560752
Active Not Recruiting
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing donor stem cell transplant. Giving a vaccine to the donors may boost the recipient's immunity to this virus and reduce the chance of CMV disease after transplant.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/18/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm, Accelerated Phase CML, BCR-ABL1 Positive, Chronic Phase CML, BCR-ABL1 Positive
Register for Updates
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
NCT02432963
Active Not Recruiting
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that have failed prior therapy, and that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
Register for Updates
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
NCT06485258
Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/17/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
NCT06890416
Not Yet Recruiting
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/17/2025
Locations: Medical Affiliated Research Center, Huntsville, Alabama +15 locations
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
NCT05470400
Completed
This is an open-label, dose-escalation study to examine the safety, tolerability, and immunogenicity of adjuvanted Fusion Peptide Vaccine alone or in prime-boost regimens with adjuvanted Trimer 4571 and Trimer 6931 vaccines in healthy adults. The hypothesis is that the vaccines will be safe, and well tolerated when administered alone, and when co-administered with HIV-1 Trimer 4571, in prime-boost regimens, and will induce detectable immune response.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/17/2025
Locations: Atlanta - Hope Clinic, Atlanta, Georgia +5 locations
Conditions: HIV
Register for Updates
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
NCT05650554
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an active control (QIVstandard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Velocity Clinical Research-Chula Vista Site Number : 8400061, Chula Vista, California +34 locations
Conditions: Influenza Immunization
Register for Updates
GVAX Plus Checkpoint Blockade in Neuroblastoma
NCT04239040
Terminated
This research clinical trial is studying the creation and administration of GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX) in combination with nivolumab and ipilimumab as a possible treatment for neuroblastoma. The names of the study drugs involved in this study are: * GVAX Vaccine, an immunotherapy developed from surgically removed tumor tissue * Nivolumab * Ipilimumab
Gender:
ALL
Ages:
1 year and above
Trial Updated:
03/14/2025
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Neuroblastoma, Pediatric Solid Tumor
Register for Updates
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
NCT05624606
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Joint Clinical Trials Huntington Park Site Number : 8400032, Huntington Park, California +24 locations
Conditions: Influenza Immunization
Register for Updates
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California +25 locations
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Register for Updates
Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
NCT05294588
Recruiting
This is a double-blind randomized controlled trial to test whether the group B meningitis vaccine 4 component Neisseria meningitidis serogroup B vaccine (BEXSEROTM) (4C-MenB), trade name Bexsero™), currently approved for use by the United States Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for protection from Neisseria meningitidis infections, also protects from Neisseria gonorrhoeae infection using controlled human experimental infec... Read More
Gender:
MALE
Ages:
Between 18 years and 35 years
Trial Updated:
03/14/2025
Locations: Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina
Conditions: Gonorrhea Male
Register for Updates
Retail COVID-19 Study
NCT06761612
Recruiting
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection. Additionally, the operational capability of retail pharmacy infrastructure to collect longitudinal data and biological samples needs to be assessed. This study aims to fill these gaps by determining correlates of protection (CoP), assessing the infrastructure's capability, and examining demographic and geographic differences in participatio... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
03/13/2025
Locations: Walgreens - 3298 S John Young Pkwy, Kissimmee, Florida +19 locations
Conditions: COVID - 19
Register for Updates